Compare HLX & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | MLTX |
|---|---|---|
| Founded | 1979 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1997 | N/A |
| Metric | HLX | MLTX |
|---|---|---|
| Price | $8.56 | $15.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $10.50 | ★ $22.22 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 02-23-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 497.36 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,312,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | $30.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.52 | $5.95 |
| 52 Week High | $8.90 | $62.75 |
| Indicator | HLX | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 48.42 |
| Support Level | $8.03 | $14.47 |
| Resistance Level | $8.53 | $16.69 |
| Average True Range (ATR) | 0.32 | 0.86 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 78.91 | 25.69 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.